| 摘要 |
<p>Compns. claimed are as BE. 742927 with identical uses. The general unit dose is claimed as 5-50 mg active ingredient, the higher dose rate of 20-100 mg. is spec. claimed for the treatment of carcinomas which are not yet malignant or of patients susceptible to carcinoma development.</p> |
